Cargando…

Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication

[Image: see text] The hepatitis C virus (HCV) nonstructural protein 3 (NS3) is both a protease, which cleaves viral and host proteins, and a helicase that separates nucleic acid strands, using ATP hydrolysis to fuel the reaction. Many antiviral drugs, and compounds in clinical trials, target the NS3...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Sourav, Weiner, Warren S., Schroeder, Chad E., Simpson, Denise S., Hanson, Alicia M., Sweeney, Noreena L., Marvin, Rachel K., Ndjomou, Jean, Kolli, Rajesh, Isailovic, Dragan, Schoenen, Frank J., Frick, David N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201343/
https://www.ncbi.nlm.nih.gov/pubmed/25126694
http://dx.doi.org/10.1021/cb500512z
_version_ 1782340162977529856
author Mukherjee, Sourav
Weiner, Warren S.
Schroeder, Chad E.
Simpson, Denise S.
Hanson, Alicia M.
Sweeney, Noreena L.
Marvin, Rachel K.
Ndjomou, Jean
Kolli, Rajesh
Isailovic, Dragan
Schoenen, Frank J.
Frick, David N.
author_facet Mukherjee, Sourav
Weiner, Warren S.
Schroeder, Chad E.
Simpson, Denise S.
Hanson, Alicia M.
Sweeney, Noreena L.
Marvin, Rachel K.
Ndjomou, Jean
Kolli, Rajesh
Isailovic, Dragan
Schoenen, Frank J.
Frick, David N.
author_sort Mukherjee, Sourav
collection PubMed
description [Image: see text] The hepatitis C virus (HCV) nonstructural protein 3 (NS3) is both a protease, which cleaves viral and host proteins, and a helicase that separates nucleic acid strands, using ATP hydrolysis to fuel the reaction. Many antiviral drugs, and compounds in clinical trials, target the NS3 protease, but few helicase inhibitors that function as antivirals have been reported. This study focuses on the analysis of the mechanism by which ebselen (2-phenyl-1,2-benzisoselenazol-3-one), a compound previously shown to be a HCV antiviral agent, inhibits the NS3 helicase. Ebselen inhibited the abilities of NS3 to unwind nucleic acids, to bind nucleic acids, and to hydrolyze ATP, and about 1 μM ebselen was sufficient to inhibit each of these activities by 50%. However, ebselen had no effect on the activity of the NS3 protease, even at 100 times higher ebselen concentrations. At concentrations below 10 μM, the ability of ebselen to inhibit HCV helicase was reversible, but prolonged incubation of HCV helicase with higher ebselen concentrations led to irreversible inhibition and the formation of covalent adducts between ebselen and all 14 cysteines present in HCV helicase. Ebselen analogues with sulfur replacing the selenium were just as potent HCV helicase inhibitors as ebselen, but the length of the linker between the phenyl and benzisoselenazol rings was critical. Modifications of the phenyl ring also affected compound potency over 30-fold, and ebselen was a far more potent helicase inhibitor than other, structurally unrelated, thiol-modifying agents. Ebselen analogues were also more effective antiviral agents, and they were less toxic to hepatocytes than ebselen. Although the above structure–activity relationship studies suggest that ebselen targets a specific site on NS3, we were unable to confirm binding to either the NS3 ATP binding site or nucleic acid binding cleft by examining the effects of ebselen on NS3 proteins lacking key cysteines.
format Online
Article
Text
id pubmed-4201343
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-42013432015-08-06 Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication Mukherjee, Sourav Weiner, Warren S. Schroeder, Chad E. Simpson, Denise S. Hanson, Alicia M. Sweeney, Noreena L. Marvin, Rachel K. Ndjomou, Jean Kolli, Rajesh Isailovic, Dragan Schoenen, Frank J. Frick, David N. ACS Chem Biol [Image: see text] The hepatitis C virus (HCV) nonstructural protein 3 (NS3) is both a protease, which cleaves viral and host proteins, and a helicase that separates nucleic acid strands, using ATP hydrolysis to fuel the reaction. Many antiviral drugs, and compounds in clinical trials, target the NS3 protease, but few helicase inhibitors that function as antivirals have been reported. This study focuses on the analysis of the mechanism by which ebselen (2-phenyl-1,2-benzisoselenazol-3-one), a compound previously shown to be a HCV antiviral agent, inhibits the NS3 helicase. Ebselen inhibited the abilities of NS3 to unwind nucleic acids, to bind nucleic acids, and to hydrolyze ATP, and about 1 μM ebselen was sufficient to inhibit each of these activities by 50%. However, ebselen had no effect on the activity of the NS3 protease, even at 100 times higher ebselen concentrations. At concentrations below 10 μM, the ability of ebselen to inhibit HCV helicase was reversible, but prolonged incubation of HCV helicase with higher ebselen concentrations led to irreversible inhibition and the formation of covalent adducts between ebselen and all 14 cysteines present in HCV helicase. Ebselen analogues with sulfur replacing the selenium were just as potent HCV helicase inhibitors as ebselen, but the length of the linker between the phenyl and benzisoselenazol rings was critical. Modifications of the phenyl ring also affected compound potency over 30-fold, and ebselen was a far more potent helicase inhibitor than other, structurally unrelated, thiol-modifying agents. Ebselen analogues were also more effective antiviral agents, and they were less toxic to hepatocytes than ebselen. Although the above structure–activity relationship studies suggest that ebselen targets a specific site on NS3, we were unable to confirm binding to either the NS3 ATP binding site or nucleic acid binding cleft by examining the effects of ebselen on NS3 proteins lacking key cysteines. American Chemical Society 2014-08-06 2014-10-17 /pmc/articles/PMC4201343/ /pubmed/25126694 http://dx.doi.org/10.1021/cb500512z Text en Copyright © 2014 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html)
spellingShingle Mukherjee, Sourav
Weiner, Warren S.
Schroeder, Chad E.
Simpson, Denise S.
Hanson, Alicia M.
Sweeney, Noreena L.
Marvin, Rachel K.
Ndjomou, Jean
Kolli, Rajesh
Isailovic, Dragan
Schoenen, Frank J.
Frick, David N.
Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication
title Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication
title_full Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication
title_fullStr Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication
title_full_unstemmed Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication
title_short Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication
title_sort ebselen inhibits hepatitis c virus ns3 helicase binding to nucleic acid and prevents viral replication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201343/
https://www.ncbi.nlm.nih.gov/pubmed/25126694
http://dx.doi.org/10.1021/cb500512z
work_keys_str_mv AT mukherjeesourav ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT weinerwarrens ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT schroederchade ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT simpsondenises ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT hansonaliciam ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT sweeneynoreenal ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT marvinrachelk ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT ndjomoujean ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT kollirajesh ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT isailovicdragan ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT schoenenfrankj ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication
AT frickdavidn ebseleninhibitshepatitiscvirusns3helicasebindingtonucleicacidandpreventsviralreplication